Literature DB >> 21830900

Highly active antiretroviral therapy in patients infected with human immunodeficiency virus increases CD40 ligand expression and IL-12 production in cells ex vivo.

Alice M Nyakeriga1, Jun Ying, Norah J Shire, Carl J Fichtenbaum, Claire A Chougnet.   

Abstract

Highly active anti-retroviral therapy (HAART) restores CD4(+) T-cell numbers in the periphery; however, its efficacy in restoring functional immunity is not fully elucidated. Here we evaluated longitudinal changes in the expression of several key markers of T-cell activation, namely CD40 ligand (CD154), OX40 (CD134), or CD69, after anti-CD3/CD28 activation, as well as levels of IL-12 production after Staphylococcus aureus Cowan stimulation in 28 HIV-infected adult patients. Patients were followed up to 12 mo post-HAART initiation. Viral burdens and CD4 cell counts were measured at the same time points. A control group of 15 HIV-uninfected adult subjects was included for comparison. Significant increases in CD40L and OX40 expression, but not of CD69 expression, were observed over time in the overall patient population, and more particularly in patients with baseline CD4 counts lower than or equal to 200 cells/μL, or those with baseline viral loads lower than or equal to 10(5) RNA copies/mL. Similar increases were seen for IL-12 production. Viral loads were inversely associated with CD40L expression or IL-12 production in a mixed linear model analysis, while CD4 counts were directly associated. CD40L expression and IL-12 production were significantly correlated. In conclusion, HAART-mediated control of viral replication led to partial restoration of CD40L upregulation/expression, and to increased IL-12 production, but the magnitude of the response depended on the baseline characteristics of the treated patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21830900      PMCID: PMC3154396          DOI: 10.1089/vim.2010.0142

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  39 in total

1.  Intracellular signaling of gp34, the OX40 ligand: induction of c-jun and c-fos mRNA expression through gp34 upon binding of its receptor, OX40.

Authors:  Y Matsumura; T Hori; S Kawamata; A Imura; T Uchiyama
Journal:  J Immunol       Date:  1999-09-15       Impact factor: 5.422

2.  Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.

Authors:  J B Angel; K G Parato; A Kumar; S Kravcik; A D Badley; C Fex; D Ashby; E Sun; D W Cameron
Journal:  J Infect Dis       Date:  2001-01-12       Impact factor: 5.226

3.  CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection.

Authors:  Christoph G Lange; Hernan Valdez; Kathy Medvik; Robert Asaad; Michael M Lederman
Journal:  Clin Immunol       Date:  2002-02       Impact factor: 3.969

4.  CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness.

Authors:  M Dybul; G Mercier; M Belson; C W Hallahan; S Liu; C Perry; B Herpin; L Ehler; R T Davey; J A Metcalf; J M Mican; R A Seder; A S Fauci
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

5.  Role of CD40 ligand signaling in defective type 1 cytokine response in human immunodeficiency virus infection.

Authors:  C S Subauste; M Wessendarp; A G Smulian; P T Frame
Journal:  J Infect Dis       Date:  2001-05-17       Impact factor: 5.226

Review 6.  The emerging role of CD40 ligand in HIV infection.

Authors:  R S Kornbluth
Journal:  J Leukoc Biol       Date:  2000-09       Impact factor: 4.962

7.  Increased priming for interleukin-12 and tumour necrosis factor alpha in CD64 monocytes in HIV infection: modulation by cytokines and therapy.

Authors:  M Bocchino; E Ledru; T Debord; M L Gougeon
Journal:  AIDS       Date:  2001-07-06       Impact factor: 4.177

8.  Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS.

Authors:  C Chougnet; S Jankelevich; K Fowke; D Liewehr; S M Steinberg; B U Mueller; P A Pizzo; R Yarchoan; G M Shearer
Journal:  J Infect Dis       Date:  2001-06-08       Impact factor: 5.226

9.  Normalization of anti-cryptococcal activity and interleukin-12 production after highly active antiretroviral therapy.

Authors:  C Monari; A Casadevall; F Baldelli; D Francisci; D Pietrella; F Bistoni; A Vecchiarelli
Journal:  AIDS       Date:  2000-12-01       Impact factor: 4.177

10.  Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease.

Authors:  Hernan Valdez; Elizabeth Connick; Kimberly Y Smith; Michael M Lederman; Ronald J Bosch; Ryung S Kim; Marty St Clair; Daniel R Kuritzkes; Harold Kessler; Lawrence Fox; Michelle Blanchard-Vargas; Alan Landay
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

View more
  2 in total

1.  Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease.

Authors:  Manoj Kumar Pandey; Reena Rani; Wujuan Zhang; Kenneth Setchell; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2012-04-30       Impact factor: 4.797

2.  Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell Responses.

Authors:  María G Alvarez; Graciela L Bertocchi; Gretchen Cooley; María C Albareda; Rodolfo Viotti; Damián E Perez-Mazliah; Bruno Lococo; Melisa Castro Eiro; Susana A Laucella; Rick L Tarleton
Journal:  PLoS Negl Trop Dis       Date:  2016-04-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.